The psilocybin-in-autism TRD program will publish or present only pilot/feasibility framing — no efficacy claim — by end of Q3.

A research team studying psilocybin for depression in autistic adults will share findings framed only as 'is this safe and doable?' — not 'does it work?' This matters because autistic people face unique risks in these studies, and researchers are being cautious before making any big claims. Real proof of effectiveness will have to wait for larger studies.

Autism populations carry heightened vulnerability and consent complexity. Responsible investigators will hedge. Early results almost never survive as efficacy in these cohorts.